A clinical trial showed that Lilly's weight loss medicine is superior to a key competitor's product. Eli Lilly (NYSE: LLY) is ...

Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

Drug manufacturers to focus on China and Japan, where penetration is low and innovation continues to emerge, Morgan Stanley ...

Eli Lilly (NYSE:LLY) reported its Q1 2025 earnings a few weeks ago, and it was said to have achieved an accelerated growth in revenue of 45% to $12.73 billion. The huge driver of this revenue ...

I believe orforglipron’s approval should finally lead to widespread and global availability of obesity medicines ... improve Eli Lilly’s leadership position in this market and these results ...

While Eli Lilly entered the market later, it is emerging as the ... "While Novo [Nordisk] took a commanding early lead in the obesity duopoly, they have ceded ground at a critical moment when ...